Skip to main content
Equibles
MDGL logo

MDGL · Madrigal Pharmaceuticals, Inc.

Track MDGL — free

Use MDGL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$541.08 -1.53 (-0.28%) At close · Sep 4
Russell 1000 member Rebalance outlook locked
Market Cap
$12.56B
Shares
23.10M

MDGL metrics

65 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$541.08
Market cap
$12.56B

Price action

19 metrics
Price change (1W)
-0.2%
Price change (30D)
+6.3%
Price change (3M)
+10.1%
Price change (6M)
+23.5%
Price change (YTD)
-6.8%
Price change (1Y)
+24.7%
Trailing year
Price change (5Y)
+571.9%
52-week high
$602.83
52-week low
$412.35
Change from 52-week high
-10.0%
Change from 52-week low
+31.6%
Annualized volatility
44.4%
Beta
0.3
RSI (14D)
55.7
Price vs SMA 50
+2.6%
Price vs SMA 200
+5.3%
Avg volume (3M)
347,766
Relative volume
0.4
Average dollar volume
$179.95M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
23.10M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
9.8×
reciprocal yield 10.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
9.8×
reciprocal yield 10.2%
P / book
24.0
reciprocal yield 4.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.6×
reciprocal yield 7.4%
EV / revenue historical average (5Y)
13.6×
reciprocal yield 7.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
—
Operating margin
-25.1%
Trailing 12 months
Net margin
-25.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$322.62M
Net income (TTM)
−$325.10M
Trailing 12 months
Diluted EPS (TTM)
$-11.28
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.56

Growth

11 metrics
Revenue growth YoY
+71.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.28B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-62.1%
Return on assets
-26.1%
Debt / equity
0.7
Current ratio
3.2
EBITDA (TTM)
−$321.10M
Free cash flow (TTM)
—
Quick ratio
2.9
Interest coverage
-10.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$48.07M
Latest balance sheet
Cash & equivalents
$292.73M
Total assets
$1.24B
Total debt
$340.79M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$197.72M
Capital expenditures (TTM)
—
R&D (TTM)
$490.14M
SG&A (TTM)
$1.01B
Stock compensation (TTM)
$121.43M
R&D / revenue
38.2%
Stock compensation / revenue
9.5%

Ownership (13F)

3 metrics
13F filers
419
13F filer change QoQ
+33
Institutional ownership
107.1%

Short interest

3 metrics
Short interest
8.8%
Latest settlement · 6.1 days to cover
Days to cover
6.1d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.71M
Insider-sentiment score
32 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1157601 CUSIP 558868105 13F (30d) 298 filings 295 filers Visit website Investor relations